COVID-19 and the SomaScan® Platform

image of the white paper

The battle against coronavirus disease 2019 (COVID-19) only begins with a test to identify who is infected and who is not. To accelerate an effective response, we have to move beyond the initial diagnosis to prognosis: Who is most susceptible to developing serious, life-threatening symptoms? Currently, there is no way to tell whether an infected individual (or an individual who may become infected) will be asymptomatic or require hospitalization. This wide variation in disease severity is, at least in part, a reflection of the myriad changes that occur within a person’s body as it fights the virus, which in turn reflect the unique biological makeup of that individual.

Download this white paper now

Download white paper

More White Papers

White paperEnsuring reproducibility in proteomics: Why coefficient of variation is a critical metric 

Learn more

White paperThe missing link between genes and disease: Discovery of protein quantitative trait loci using high-plex protein profiling

Learn more

White paperThe SomaScan® Assay enables discovery of blood-based biomarkers in neurodegenerative diseases

Learn more

Explore external publications in our interactive viewer